Ryan Ramanujam
Overview
Explore the profile of Ryan Ramanujam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicholas R, Rodgers J, Witts J, Lerede A, Friede T, Hillert J, et al.
Ther Adv Neurol Disord
. 2023 Sep;
16:17562864231198963.
PMID: 37771841
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing-remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising...
2.
Boles G, Hillert J, Ramanujam R, Westerlind H, Olsson T, Kockum I, et al.
Mult Scler
. 2023 Jul;
29(10):1209-1215.
PMID: 37435869
Background: The two main phenotypes of multiple sclerosis (MS), primary progressive (PPMS) and relapsing Onset (ROMS), show clinical and demographic differences suggesting possible differential risk mechanisms. Understanding the heritable features...
3.
Forsberg L, Spelman T, Klyve P, Manouchehrinia A, Ramanujam R, Mouresan E, et al.
Mult Scler J Exp Transl Clin
. 2023 Feb;
9(1):20552173231153557.
PMID: 36816812
Background: To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease...
4.
Oviedo Querejazu M, Dunn N, Ramanujam R, Ryner M, Auer M, Jensen P, et al.
Mult Scler Relat Disord
. 2022 May;
63:103815.
PMID: 35508100
Interferon beta (IFNβ) is a first line therapy for treatment of multiple sclerosis (MS). However, up to 47% of treated patients will develop neutralizing anti-drug antibodies (NAbs) against IFNβ, which...
5.
Manouchehrinia A, Kingwell E, Zhu F, Tremlett H, Hillert J, Ramanujam R
Mult Scler
. 2021 Jan;
27(12):1875-1883.
PMID: 33487091
Background: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. Objective: The objective of this study is to create a...
6.
Ramanujam R, Zhu F, Fink K, Karrenbauer V, Lorscheider J, Benkert P, et al.
Mult Scler
. 2020 Dec;
27(8):1240-1249.
PMID: 33263261
Background: The absence of reliable imaging or biological markers of phenotype transition in multiple sclerosis (MS) makes assignment of current phenotype status difficult. Objective: The authors sought to determine whether...
7.
Riihimaki H, Chacholski W, Theorell J, Hillert J, Ramanujam R
BMC Bioinformatics
. 2020 Jul;
21(1):336.
PMID: 32727348
Background: Machine learning models for repeated measurements are limited. Using topological data analysis (TDA), we present a classifier for repeated measurements which samples from the data space and builds a...
8.
Crielaard L, Kavaliunas A, Ramanujam R, Olsson T, Hillert J, Stridh P, et al.
J Neurol Neurosurg Psychiatry
. 2019 Mar;
90(7):761-767.
PMID: 30824631
Objective: Benign multiple sclerosis (BMS) is often defined by the Expanded Disability Status Scale (EDSS) score of ≤3.0 after ≥15 years of disease duration. This classification's clinical relevance remains unclear...
9.
Jensen P, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, et al.
J Neuroimmunol
. 2018 Nov;
326:19-27.
PMID: 30447419
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested...
10.
Manouchehrinia A, Hedstrom A, Alfredsson L, Olsson T, Hillert J, Ramanujam R
Front Neurol
. 2018 Jun;
9:232.
PMID: 29867705
Both high body mass index (BMI) and smoking tobacco are known risk factors for developing multiple sclerosis (MS). However, it is unclear whether BMI, like smoking, is a risk factor...